| Ytd | -47.64% | |
| 1y | -49.45% |
| Open | 3.14 | Prev Close | 3.16 | Low | 3.04 | High | 3.26 | Mkt Cap | 307.99M |
| Vol | 1.54M | Avg Vol | 1.85M | EPS | -1.18 | P/E | N/A | Forward P/E | 71.53 |
| Beta | 1.89 | Short Ratio | 4.83 | Inst. Own | 103.89% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 4.60 | 200-d Avg | 5.15 | 1yr Est | 19.41 |
MYGN News
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in
Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Wei
NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds
Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN)
Assenagon Asset Management S.A. decreased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 28
Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free R
Myriad Genetics (MYGN) Securities Investigation Notice - Levi and Korsinsky PR Newswire NEW YORK, Au
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughl
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation fi
LOS ANGELES--(BUSINESS WIRE)---- $MYGN--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered L
Myriad Genetics missed Q2 2026 revenue consensus by roughly 7%-8% -- $190.7 million against Wall Str
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating pot
NEW YORK--(BUSINESS WIRE)--On May 5, 2026, Myriad Genetics (NASDAQ: MYGN) reaffirmed adjusted EBITDA
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Myriad Ge
Myriad Genetics Investigation Notice: Levi and Korsinsky Notifies Investors of Pending Investigation
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just t
Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and
Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Dow up 0.38%, NASDAQ up 0.25%, S&P 500 up 0.22%. Consumer discretionary shares up 5.6%, material
Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-
U.S. stock futures rise, Nasdaq 100 up 300 points. Apple Inc shares fall 7.4% despite beating analys
Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr
Myriad Genetics stock fell after hours after weak Q2 results, lower guidance and an operating loss.
Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript
Myriad Genetics (MYGN) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus
Gainers Scribe Therapeutics (NASDAQ:SCTX) shares increased by 12.7% to $23.0 during Thursday's
Myriad Genetics (NASDAQ:MYGN) lowers FY2026 sales outlook from $860.000 million-$880.000 million to
Highl ights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a
Gainers Nuwellis (NASDAQ:NUWE) stock rose 40.2% to $2.65 during Wednesday's after-market sessio
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) affirms FY2026 sales outlook from $860.000 million-$880.000 million to
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.09) per share which missed the analys
Myriad Genetics Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicin
UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price tar
Wells Fargo analyst Brandon Couillard maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight
Myriad Genetics (NASDAQ:MYGN) sees FY2026 sales of $860.000 million-$880.000 million vs $867.455 mil
Myriad Genetics (NASDAQ:MYGN) reported quarterly earnings of $0.04 per share which beat the analyst
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine